CREBBP and lymphoma: We propose that lack of intrafollicular CD4 + T cells can be considered as a surrogate biomarker of immune escape in a manner analogous to the case of CREBBP mutant lymphomas, which indeed benefit from HDAC3-selective inhibitors to promote immune-related activities [47].